Oppenheimer Asset Management Inc. Purchases New Shares in CVS Health Corporation $CVS

Posted by Stanley Muller on Aug 15th, 2026

Oppenheimer Asset Management Inc. acquired a new stake in CVS Health Corporation (NYSE:CVS – Free Report) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 479,674 shares of the pharmacy operator’s stock, valued at approximately $49,622,000.

Several other large investors also recently made changes to their positions in the business. Elevation Wealth Partners LLC increased its stake in shares of CVS Health by 41.8% in the second quarter. Elevation Wealth Partners LLC now owns 356 shares of the pharmacy operator’s stock valued at $37,000 after buying an additional 105 shares in the last quarter. Apella Capital LLC lifted its position in CVS Health by 1.7% during the 2nd quarter. Apella Capital LLC now owns 6,940 shares of the pharmacy operator’s stock worth $724,000 after buying an additional 117 shares in the last quarter. CYBER HORNET ETFs LLC lifted its position in CVS Health by 4.1% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after buying an additional 134 shares in the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in CVS Health by 4.7% during the 4th quarter. Moss Adams Wealth Advisors LLC now owns 3,016 shares of the pharmacy operator’s stock worth $239,000 after acquiring an additional 135 shares during the last quarter. Finally, Northwestern Mutual Investment Management Company LLC increased its position in CVS Health by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 40,560 shares of the pharmacy operator’s stock valued at $3,219,000 after acquiring an additional 136 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

CVS Health stock opened at $97.09 on Friday. The company has a market cap of $124.18 billion, a PE ratio of 25.69, a PEG ratio of 0.91 and a beta of 0.61. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. CVS Health Corporation has a 1 year low of $67.42 and a 1 year high of $110.68. The company’s 50-day moving average is $102.52 and its two-hundred day moving average is $88.23.

CVS Health (NYSE:CVS – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to analysts’ expectations of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. Equities analysts anticipate that CVS Health Corporation will post 8.02 earnings per share for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s payout ratio is currently 70.37%.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director owned 4,824,799 shares in the company, valued at approximately $450,877,466.55. The trade was a 7.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 3,372,000 shares of company stock worth $317,473,598. 0.85% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

CVS has been the subject of a number of research analyst reports. DA Davidson boosted their target price on shares of CVS Health from $80.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Cantor Fitzgerald increased their price target on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. Piper Sandler reissued an “overweight” rating and issued a $113.00 price target on shares of CVS Health in a report on Monday, June 1st. Wells Fargo & Company boosted their price objective on shares of CVS Health from $103.00 to $123.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, Wall Street Zen upgraded CVS Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Twenty-two research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and an average price target of $106.75.

Get Our Latest Analysis on CVS Health

CVS Health Company Profile

(Free Report)

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.